ArborGen Holdings reported a solid FY26 with record revenue driven by Brazil expansion and a 31% EBITDA increase, offsetting a challenging US market. Leadership changes and operational discipline mark the company’s path forward.
- FY26 revenue up 8% to $68.2 million
- Adjusted US GAAP EBITDA rises 31% to $11.5 million
- Net loss narrows to $7.5 million from $21.5 million
- Strong growth and margin focus in Brazil market
- CEO Justin Birch resigns; Patrick Cumbie named interim CEO
Record Revenue and Earnings Growth Amid US Market Challenges
ArborGen Holdings Limited (NZX:ARB) closed FY26 with its highest revenue in five years, hitting US$68.2 million; an 8% increase year-on-year. This was largely propelled by robust demand and higher average selling prices in Brazil, which offset a 4% decline in seedling volumes in the US South market.
Adjusted US GAAP EBITDA jumped 31% to US$11.5 million, reflecting the company's ongoing focus on operational efficiency and a higher-value product mix. Despite this progress, ArborGen reported a net loss after tax of US$7.5 million, a significant improvement from the US$21.5 million loss in FY25, which included a large non-cash impairment charge.
Brazil Drives Growth with Advanced Genetics and Market Expansion
Brazil remains ArborGen’s growth engine, with seedling volumes rising 5% and revenue up 14% in local currency. The company has strategically shifted the majority of its Erval Grande nursery to pine production to capitalise on strengthening plywood and sawtimber markets. Demand for higher-value protected clones surged 25% year-on-year, underscoring customer recognition of the benefits of ArborGen’s proprietary genetics.
Operational improvements in Brazil included enhanced cost control, yield optimisation, and expanded production scheduling to mitigate weather variability; a recurring challenge in the region. ArborGen is also broadening its geographic reach within Brazil and has begun supplying high-quality US pine seeds to non-competing local businesses, signalling cross-market opportunities.
US South Market Faces Structural Headwinds, Focus Shifts to Value
The US South timber industry continues to grapple with structural shifts, including pulp and paper mill closures and reduced sawtimber demand due to high interest rates. These factors have led to conservative planting behaviour among landowners, resulting in a 4% drop in seedling sales volumes.
ArborGen is responding by realigning its US operations to current market conditions through cost management, workforce restructuring, and nursery consolidation, while maintaining the capacity to scale when demand recovers. The company is concentrating on higher-margin products such as MCP advanced genetics and containerised seedlings, supported by a rebranding effort that clarifies product attributes with customers.
Strategic agreements with key customers have helped mitigate sales risks, and early harvest data confirm the superior performance of MCP seedlings, bolstering customer confidence in advanced genetics adoption.
Leadership Transition and Strengthened Operational Platform
Post-financial year end, CEO Justin Birch resigned after three years at the helm, with Patrick Cumbie appointed interim CEO. Cumbie, a seasoned forestry executive with over 23 years of industry experience, previously served as Vice President of Product Development at ArborGen. The Board has initiated a structured search for a permanent CEO.
Operationally, ArborGen completed the rollout of a new ERP system in the US, enhancing data security and decision-making speed. The company also invested US$4.1 million in capital expenditure, focusing on inventory build, IT upgrades, and container seedling production capacity.
On the balance sheet front, ArborGen held US$2.2 million in cash with net debt at US$25.2 million, reflecting ongoing strategic investments. The company is actively marketing its Ridgeville headquarters building, with sale proceeds earmarked for debt reduction.
Climate Resilience and Long-Term Value Creation
ArborGen continues to address climate risks by diversifying its production footprint across Brazil and the US and investing in drought- and disease-resistant genetics. The company is also engaging with the emerging carbon credit market, positioning itself as a supplier of choice for carbon forestry projects.
The company’s long-term strategy remains focused on increasing adoption of advanced genetics and building the operational infrastructure to reliably supply these products at scale. ArborGen’s dual pathway strategy targets growth in both the US and Brazil, leveraging its science platform and deep customer relationships to create sustained shareholder value.
Governance and Risk Management Aligned with NZX Standards
ArborGen’s corporate governance practices align closely with the NZX Corporate Governance Code, with a majority independent Board and robust risk management frameworks. The company maintains comprehensive oversight of financial reporting, operational risks, and climate-related challenges, supported by an active Audit Committee and transparent disclosure policies.
Despite the Chairman Dave Knott being a substantial shareholder and thus non-independent by NZX definition, the Board considers his leadership appropriate given his alignment with shareholder interests and the presence of a majority of independent Directors.
Bottom Line?
ArborGen’s FY26 results highlight resilience and strategic focus amid market headwinds, but the US structural challenges and leadership transition warrant close attention as the company pursues growth in Brazil and advanced genetics adoption.
Questions in the middle?
- How will ArborGen’s new CEO shape the company’s strategy in a challenging US market?
- Can the company sustain Brazil’s growth momentum amid increasing competition and pricing pressure?
- What impact will climate variability and weather events have on seedling supply and operational costs going forward?